

Hämatologie im Wandel

Multiples Myelom –

Konzepte der Deutschen Studiengruppe Multiples Myelom

Stefan Knop

Medizinische Klinik und Poliklinik II

Universitätsklinikum Würzburg

Frankfurt, 30. Februar 2013


deutsche studiengruppe
multiples myelom

dsmm


doing studies on multiple myeloma



Wahl der Primärtherapie beim Myelompatienten



Treatment Schedule



Multivariate Analyse


PFS (allo SCT zensiert)			OS		
Variable	HR	<i>p</i>	Variable	HR	<i>p</i>
Arm	0.74	.002	Arm	0.70	.013
WHO	1.22	.005	WHO	1.49	<.001
IgA	1.62	.002	IgA	1.82	.01
IgG	1.33	.041	IgG	1.71	.008
LDH	1.25	.10	LDH	1.59	.006
ISS	1.25	.001	ISS	1.47	<.001
13q-	1.43	.001	13q-	1.62	.002
Studiengruppe	0.81	.039	Studiengruppe	0.73	.031

Aber: Bislang keine Korrelation mit Ansprechtiefe nach erster HD!

DSMM XIV Study



n= 406 patients; Study schedule





Randomisation between 2nd Mel200 vs allo SCT for all subjects with PR or SD → donor search for MRD or MUD

↓ MRD assessment by flow cytometry

Assumption for induction: bRAD 10% CR, VRD 15% CR;
Testing on non-inferiority for bRAD, i.e. < 15% „real“ difference

bRAD versus VRd as Induction Protocols

DSMM XIV Study



bRAD: LMWH mandatory; VRD: Acyclovir mandatory, ASS 100 mg/d recommended


Geplante Interimsanalyse; Patientencharakteristika, n=187

Auswertbar (n)	187
Geschlecht: männl./weibl. (n)	124/63
Medianes Alter, Jahre (Spannbreite)	55 (30 – 66)
Medianes Intervall Dx-Therapie, Mo. (Spannbreite)	1,2 (0,1 – 136)
ECOG Zustand >1, n (%)	19 (10,2)
ISS-Stadien 2+3, n (%)	99 (52,9)
Durie&Salmon Stadium III, %	152 (81,3)
LDH > ob. Normwert, n (%)	37 (19,8)
β_2 Mikroglobulin > 3,5 g/l	66 (35,3)
Molekulare Zytogenetik, n(%)	
del 13q	46 (24,6)
t(4;14)	18 (9,6)
del 17p	14 (7,5)
t(14;16)	3 (2)

Ansprechen auf die Induktion in der DSMM XII-Studie




n= 187 Patienten; Geplante Interimsanalyse



sCR/CR/VGPR = 46 %

GEM05MENOS65

De “**nov**o” symptomatic MM <65 yrs



*3 MU/sc 3 times a week

**100 mg/day

& Thal 100 mg/day. Bortezomib 1.3 mg/m² days 1,4,8,11 every 3 months

Risk-stratified DSMM V – Trial

Enrolment 10/01–3/07; $n = 381$

